Simpson R A, Dickinson T, Porter K E, London N J, Hemingway D M
University Department of Surgery and Department of General and Gastrointestinal Surgery, Leicester Royal Infirmary, Leicester LE2 7LX, UK.
Br J Surg. 2000 Oct;87(10):1409-13. doi: 10.1046/j.1365-2168.2000.01536.x.
The aim was to assess the role of plasma Big Endothelin (ET) 1 levels as a marker of disease presence and stage in colorectal adenocarcinoma.
Big ET-1 was measured in the plasma of 37 patients with colorectal cancer. Preoperative systemic plasma levels of Big ET-1 in patients with cancer were compared with levels in 20 age- and sex-matched controls. Portal plasma samples were collected at operation in addition to peripheral venous samples. Immunohistochemical staining for Big ET-1 was performed on a selection of primary tumour specimens and liver metastases.
Median (range) preoperative systemic plasma levels of Big ET-1 were significantly higher in patients with cancer than in controls (1.0 (0.3-9.7) versus 0.2 (0.0-6.0) fmol/ml; P = 0.0001). Intraoperative portal plasma levels of Big ET-1 were significantly higher in patients with Dukes' 'D' disease than in patients with Dukes' A, B and C disease (2.1 (1.4-10.0) versus 1.2 (0.3-6.6) fmol/ml; P = 0. 01). Similarly, systemic plasma levels were significantly higher in patients with Dukes' 'D' disease than in those with localized disease (1.9 (1.2-9.7) versus 1.2 (0.2-8.3) fmol/ml; P = 0.01). The presence of microvascular invasion in the tumour specimens was associated with a significantly raised portal plasma level of Big ET-1 (1.6 (1.5-2.1) versus 1.1 (0.8-1.3) fmol/ml; P = 0.04). Immunohistochemistry localized Big ET-1 to the cancer epithelial cells.
The plasma level of Big ET-1 is significantly raised in patients with colorectal cancer. Patients with liver metastases have significantly higher levels than those with localized disease.
目的是评估血浆大内皮素（ET）-1水平作为结直肠癌疾病存在和分期标志物的作用。
检测了37例结直肠癌患者血浆中的大ET-1。将癌症患者术前全身血浆大ET-1水平与20例年龄和性别匹配的对照者的水平进行比较。除外周静脉血样本外，术中还采集门静脉血浆样本。对部分原发性肿瘤标本和肝转移灶进行大ET-1免疫组化染色。
癌症患者术前全身血浆大ET-1中位数（范围）显著高于对照组（1.0（0.3 - 9.7）对0.2（0.0 - 6.0）fmol/ml；P = 0.0001）。Dukes‘D期疾病患者术中门静脉血浆大ET-1水平显著高于Dukes’A、B和C期疾病患者（2.1（1.4 - 10.0）对1.2（0.3 - 6.6）fmol/ml；P = 0.01）。同样，Dukes‘D期疾病患者的全身血浆水平显著高于局限性疾病患者（1.9（1.2 - 9.7）对1.2（0.2 - 8.3）fmol/ml；P = 0.01）。肿瘤标本中存在微血管侵犯与门静脉血浆大ET-1水平显著升高相关（1.6（1.5 - 2.1）对1.1（0.8 - 1.3）fmol/ml；P = 0.04）。免疫组化将大ET-1定位于癌上皮细胞。
结直肠癌患者血浆大ET-1水平显著升高。有肝转移的患者水平显著高于局限性疾病患者。
